New Therapeutic Paradigm for Diabetic Kidney Disease Focused on Finerenone

Diabetic kidney disease (DKD) is a common and serious complication of diabetes, leading to endstage kidney disease and heightened cardiovascular (CV) risk. Traditional management, including strict glycemic and blood pressure control with renin–angiotensin–aldosterone system (RAAS) blockade, has only partially mitigated progression. Recent therapeutic advances, notably sodium glucose cotransporter 2 (SGLT2) inhibitors and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone, have transformed the DKD treatment landscape. Finerenone selectively antagonizes the mineralocorticoid receptor, reducing pro-inflammatory and pro-fibrotic signaling in kidneys and heart. In the phase 3 FIDELIO-DKD trial (patients with type 2 diabetes and chronic kidney disease [CKD]), finerenone significantly slowed CKD progression and reduced a composite kidney outcome by 18% relative risk versus placebo. The FIGARO-DKD trial (including earlier-stage CKD) demonstrated a significant reduction in major CV events with finerenone. Pooled analysis confirmed improved cardiorenal outcomes. The efficacy of finerenone is additive to RAAS blockers and SGLT2 inhibitors, as combination therapy further decreases albuminuria without excessive adverse effects. Compared to steroidal MRAs (spironolactone), finerenone shows a more favorable safety profile—lower risk of hyperkalemia and no anti-androgenic side effects. Incorporating finerenone into DKD management marks a new paradigm, offering improved renal and CV protection on top of existing standard care. Proper patient selection (estimated glomerular filtration rate ≥ 25 mL/min/1.73 m<sup>2</sup>, persistent albuminuria despite maximal RAAS blockade, normal serum potassium) and monitoring for hyperkalemia are essential. Future research should explore finerenone in broader CKD populations, optimal combination strategies, and long-term outcomes to further refine DKD therapy.